# De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

> **NCT04675827** · PHASE2 · TERMINATED · sponsor: **Jules Bordet Institute** · enrollment: 139 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- ER-Negative Breast Cancer
- PR-Negative Breast Cancer
- Node-negative Breast Cancer

## Interventions

- **DRUG:** Pertuzumab and tratuzumab fixed dose combination
- **DRUG:** Trastuzumab emtansine

## Key facts

- **NCT ID:** NCT04675827
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-17
- **Primary completion:** 2024-11-26
- **Final completion:** 2024-11-26
- **Target enrollment:** 139 (ACTUAL)
- **Why stopped:** Serious concerns on the slow recruitment of the study that impacts the robustness of the scientific rationale and the study financial provision. It aims to assess carefully the situation and to evaluate the potential solutions to overcome the issues.
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04675827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04675827, "De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04675827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*